The Oral Solid Dosage Contract Manufacturing Market To Outshine Its Yesteryears’

Posted by Merin John on April 28th, 2021

Market consolidation strategies to be centered around acquisition of key technologies and specialty pharma companies.

Solid dosage continues to remain the most preferred drug delivery form, used across a wide spectrum of pharmaceutical landscape, pushing the global oral solid dosage (OSD) contract manufacturing market to a promising US$ 21.5 Billion cap, in 2019, predicts Persistence Market Research, in its recently released study on the global oral solid dosage contract manufacturing landscape.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25768

Company Profiles

Recipharm AB

AbbVie Contract Manufacturing

Patheon N.V.

Catalent Inc.

NextPharma

Capsugel (Lonza Group AG)

Aurobindo Pharma Limited (AuroSource)

Siegfried AG

Piramal Pharma Solutions

CordenPharma

Apart from being more cost-effective (compared to the novel treatment alternatives and increasing number of biologics) and patient complaint, oral dosage provides increased physical and chemical stability, controlled-release options, and superior ease of handling.

The global oral solid dosage contract manufacturing market is estimated to grow at a high CAGR of 5.8 percent, through the forecast period of 2017-2028.

“The market will continue to perform immensely well, given the unrivaled demand for generics, in the coming years. Key companies operating in the oral solid dosage contract manufacturing landscape, anticipate substantial market growth through 2028, given the growing demand in emerging markets, continuing novel pharmaceutical formulations, and industry consolidation”, Principal Analyst, Pharmaceutical Domain, Persistence Market Research